# BioMarin Pharmaceutical Inc. (BMRN) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $55.66, market value $10.8 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). BioMarin Pharmaceutical Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 3.2×**. Each dollar of revenue is priced at 3.2×.
- **Price / book: 1.8×**. The shares trade at 1.8× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 33.3×**. Enterprise value is 33.3× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 6.9%** (5-yr avg 2.4%). Free cash flow equals 6.9% of the market value, above its five-year average of 2.4%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.

## Profitability
- **Operating margin: 4.4%**. 4.4% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: 10.8%**. 10.8% of each dollar of sales reaches the bottom line.
- **Return on equity: 5.7%**. 5.7% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 2.2%**. Return on all capital, debt included, is 2.2%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 1.0%**. Each dollar of assets produces 1.0% of profit.

## Growth
- **Revenue growth (1 yr): 12.9%** (3-yr 15.4%/yr, 5-yr 11.6%/yr). Revenue grew 12.9% over the last year, against 11.6% a year compounded over five years.
- **EPS growth (1 yr): -18.6%** (3-yr 33.9%/yr, 5-yr -16.7%/yr). Earnings per share fell 18.6%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 136.3%/yr**. Free cash flow has compounded at 136.3% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.10**. Debt is 0.10 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. BioMarin Pharmaceutical Inc. holds more cash than debt.
- **Current ratio: 5.21** (quick 5.21). Current assets cover the next year's liabilities 5.21 times.
- **Altman Z-score: 6.52**. A Z-score of 6.52 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. BioMarin Pharmaceutical Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (27 analysts). 27 analysts cover BioMarin Pharmaceutical Inc.; the consensus is buy, with an average price target of $91.56 (+64% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 5.3%** (YTD -6.3%, 3-mo -8.3%). The shares are up 5.3% over twelve months including dividends.
- **From 52-week high: -21.6%** (13.0% above the low). Trading 22% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 43**. An RSI of 43 is neutral.
- **Beta (1 yr): 0.38** (volatility 35%). Beta of 0.38 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BMRN · Page: https://foliofundamentals.com/stocks/bmrn

Not investment advice.